Enterprise Value

727.6B

Cash

3.041B

Avg Qtr Burn

N/A

Short % of Float

0.57%

Insider Ownership

0.16%

Institutional Own.

84.39%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Jaypirca® Pirtobrutinib Details
Cancer, Chronic lymphocytic leukemia, Lymphoma, Blood cancer, Small lymphocytic lymphoma

Approved

Quarterly sales

Jaypirca (pirtobrutinib) Details
Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma

Approved

Quarterly sales

Jardiance® (empagliflozin) (anti-SGLT2) Details
Diabetes, Type 2 diabetes, Chronic kidney disease

Approved

Quarterly sales

Donanemab Details
Alzheimer's disease

BLA

Acceptance for review

Lebrikizumab Details
Skin disease/disorder, Atopic dermatitis

BLA

FDA meeting

Retevmo +/- pembrolizumab Details
Non-small cell lung carcinoma

Phase 3

Data readout

Phase 3

Data readout

Abemaciclib Details
Castration-resistant prostate cancer

Phase 3

Data readout

Remternetug Details
Alzheimer's disease

Phase 3

Data readout

Orforglipron Details
Type 1 diabetes

Phase 3

Update

Phase 3

Update

Retevmo Details
Medullary Thyroid Cancer

Phase 3

Update

Phase 3

Update

Mirikizumab Details
Crohns disease

Phase 3

Update

Pirtobrutinib Details
Lymphoma, Cancer, Blood cancer, Chronic lymphocytic leukemia

Phase 3

Update

Phase 3

Initiation

Phase 2b

Update

Phase 2

Update

Peresolimab /LY3462817 Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Update

DC-853 Details
Inflammatory disease, Autoimmune disease

Phase 1

Update

AK-OTOF Details
OTOF-mediated hearing loss

Phase 1

Update